RBC cuts Fisher & Paykel stock rating, lowers price target to NZD29

Published 28/05/2025, 16:42
RBC cuts Fisher & Paykel stock rating, lowers price target to NZD29

On Wednesday, RBC Capital Markets adjusted its stance on Fisher & Paykel Healthcare (FPH:NZ) (OTC:FSPKF), downgrading the stock from Sector Perform to Underperform and revising the price target down to NZD29.00 from the previous NZD30.00. The downgrade followed the company’s announcement of its financial results for the fiscal year 2025, which, while surpassing both RBC’s and the consensus estimates, revealed a notable deceleration in the growth of revenue from hospital new application consumables and homecare consumables.

RBC Capital Markets expressed concerns regarding Fisher & Paykel Healthcare’s future performance, citing the company’s provided financial guidance for fiscal year 2026 as a slight letdown. In response to these developments, RBC Capital has reduced its earnings forecasts for the healthcare equipment provider.

The revised price target of NZD29.00, down from NZD30.00, reflects a more cautious outlook on Fisher & Paykel Healthcare’s stock. RBC Capital’s decision to downgrade the stock to Underperform is rooted in their assessment that the company’s current valuation is steep when juxtaposed with its projected earnings trajectory.

In their commentary, RBC Capital highlighted the sluggish growth in key product segments as a significant factor behind the downgrade. The firm’s analysts pointed out that despite Fisher & Paykel Healthcare’s fiscal year 2025 results exceeding expectations, the slowdown in growth and the less-than-optimistic guidance for the following year prompted a reassessment of the stock’s potential.

The current analysis by RBC Capital Markets suggests investors may need to temper their expectations for Fisher & Paykel Healthcare’s performance in the near term. The healthcare company’s stock will be closely watched as the market digests this new information and adjusts to the revised outlook provided by RBC Capital.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.